Drupal.behaviors.print = function(context) {window.print();window.close();}>
RXi Releases Positive Safety Data on Scarring Drug, Posts Higher Q3 Loss on Dividend
November 15, 2012
RXi Releases Positive Safety Data on Scarring Drug, Posts Higher Q3 Loss on Dividend
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Phase I Data Shows RXi Anti-Scarring Drug Safe, Well-tolerated
June 6, 2013 / Gene Silencing News
Following Private Placement, RXi Has Funds to Last into 2015
April 4, 2013 / Gene Silencing News
RXi Releases Blinded Phase I Data Hinting at Efficacy of Anti-Scarring Drug, On Track for Phase II
February 21, 2013 / Gene Silencing News
RXi Begins Second Phase I Trial of Anti-Scarring Drug
December 6, 2012 / Gene Silencing News
RXi Completes Enrollment in Phase I Anti-Scarring Drug Trial
September 27, 2012 / Gene Silencing News